Diazoxide labels and packages: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Diazoxide}} {{CMG}}; {{AE}} {{SS}} ==Labels and Packages== {| |thumb|800px |} {| |thumb|800px |} <ref name="da...")
 
No edit summary
Line 5: Line 5:
==Labels and Packages==
==Labels and Packages==
{|
{|
|[[File:Amiloride01.jpg|thumb|800px]]
|[[File:Amiloride02.jpg|thumb|800px]]
|}
|}


{|
{|
|[[File:Amiloride01.jpg|thumb|800px]]
|[[File:Amiloride03—.jpg|thumb|800px]]
|}
|}



Revision as of 22:32, 26 February 2014

Diazoxide
PROGLYCEM® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Diazoxide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Labels and Packages

File:Amiloride03—.jpg

[1]

References

  1. "PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC]". Retrieved 26 February 2014.

Template:Nonsympatholytic vasodilatory antihypertensives Template:Other therapeutic products Template:Channel openers